Business
Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001TM
Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001TM.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n Bioasis \n Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company”), \n a pre-clinical, research-stage biopharmaceutical company developing its \n proprietary xB3 TM platform technology for the \n delivery of therapeutics across the blood-brain barrier (BBB) and the \n treatment of CNS disorders in areas of high unmet medical need, \n including brain cancers and neurodegenerative diseases, today announced \n data using the Company’s lead investigational candidate xB3-001 \n in an advanced positron emission tomography and computed \n tomography (PET/CT) imaging study in non-human primates suggest \n selective peripheral distribution. The data also indicates penetration \n of the lymphatic system with xB3-001.\n \n \n “These findings with xB3-001 suggest that the Bioasis \n platform can enhance the distribution of treatments that have their \n efficacy limited by inability to penetrate relevant tissue \n compartments,” said Prof. John H. Krystal, M.D., chairman, Bioasis \n scientific advisory board (SAB); Robert L. McNeil, Jr., professor of \n translational research, chair of the department of psychiatry, and \n professor of neuroscience at the Yale University School of Medicine and \n chief of psychiatry at Yale-New Haven Hospital.\n \n \n In collaboration with Invicro \n LLC., whole-body distribution of xB3-001 was examined in \n the study using advanced PET/CT imaging in non-human primates. Data from \n this study suggest a more selective peripheral distribution pattern for \n xB3-001 compared to trastuzumab alone. Importantly, the data \n also indicate that the xB3 platform has the potential to \n penetrate the lymphatic system as shown by the accumulation of xB3-001 \n in the cervical lymph nodes, which is not seen in trastuzumab alone.\n \n \n “Together, both the peripheral distribution of xB3-001 and \n penetration of the lymph nodes may indicate additional benefits of xB3 \n fusions for patients with neurological and oncological diseases,” said \n Mark Day, Ph.D., lead investigator of the research; director, president \n and chief executive officer, Bioasis. “The potential of these findings \n with the xB3 platform are truly exciting and we look forward \n to conducting additional research as it potentially opens signi...